Innate Pharma S.A.

NASDAQ: IPHA
Share price (12/20/24): $2.05
Market cap (12/20/24): $165 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/23 FY 2023

ended 12/31/22 FY 2022 – amended

ended 12/31/22 FY 2022

ended 12/31/21 FY 2021

ended 12/31/20 FY 2020

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Shelf registration

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Bpifrance Participations SA

Bpifrance Participations SA

Bpifrance Participations SA

Novo Nordisk A/S

AstraZeneca PLC

News Filter

To Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Presents Lacutamab Improved Health-Related Quality of Life Data at Ash 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce Up to $7.9m Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Highlights Abstracts Selected for the ASH Annual Meeting 2024

Releases Its 2025 Financial Calendar

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness

Correspondence with the SEC